Diacerein

双醋瑞因

Report date: 2026/04/25 20:00:23
NME

Base Information

Drug NameDiacerein
Drug Alias Name1,8-二乙酰基-3-羧基蒽醌DiacerheinGalaxdar二乙酰二氢蒽羧酸达赛瑞英 +[20] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInterleukin-1 beta inhibitors
TargetsInterleukin-1 beta
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)OverweightDiabetes Complications +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[25] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesUniversitas SriwijayaINTERNATIONAL BIO SERVICES CO LTDTrb Chemedica Ag +[6] 
Inactive CompaniesAns PharmaUniversidade Federal Do Rio De JaneiroLaboratoires Negma +[5] 
Active IndicationsCoronavirus Disease 2019 (COVID-19)Diabetes Mellitus, Type 2Diabetes Mellitus +[6] 
Inactive IndicationsOverweightDiabetes ComplicationsObesity +[6] 

Other Information

ATC CodeM01AX21
Related LinksWikipediaKEGG